Investors

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, which is designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its serious side effects, and cumbersome treatment management. The company aims to relieve patients and their healthcare providers from some of warfarin’s greatest challenges.

The company’s Phase 3-ready drug candidate, tecarfarin, is a new VKA chronic anticoagulant with extensive data showing its potential to be superior to warfarin, resulting in fewer adverse events such as strokes, heart attacks, bleeds and deaths. Tecarfarin received an orphan drug designation for heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib). Cadrenal is opportunistically pursuing pivotal clinical trials along with clinical and commercial partnership opportunities. The company’s plans also include studying patients with mechanical heart valves experiencing anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment.

Tecarfarin is metabolized via a different pathway than warfarin and data shows that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range that inversely correlates with major events.

With the only new VKA blood thinner being developed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo to innovate a new anticoagulant providing better care for underserved patients.